Serdia Pharma bags CDSCO approval for anti-diabetic FDC of extended-release Gliclazide 60mg plus Metformin 1000mg tablet
In a significant development, Serdia Pharmaceuticals (India) Pvt. Ltd. has got approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market an anti-diabetic fixed-dose combination uncoated bilayer tablet comprising Gliclazide 60mg (as extended-release) plus Metformin Hydrochloride IP 1000mg (as extended-release) tablet.
Gliclazide plus Metformin is a combination of two antidiabetic medicines, used in the treatment of type 2 diabetes mellitus (T2DM). It improves blood glucose levels in adults when taken along with proper diet and regular exercise.
For more information, check out the full story on the link below: